HPV Infections Clinical Trial
Official title:
Crossover Vaccination of Women Previously Randomized Into Protocol 04-C-N191(NCI)/IC-200403(INCIENSA)
Verified date | March 17, 2015 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Background:
- National Cancer Institute Protocol 04-C-N191, also known as the Costa Rica Vaccine Trial,
was a double-blind controlled study of the effectiveness of an experimental human
papillomavirus (HPV) vaccine in preventing cervical cancer in young women in Costa Rica.
Costa Rica was part of the first large study to show the association between HPV and cervical
cancer, and the study contributed greatly to the understanding of this association. The women
who have participated in the vaccine trial in Costa Rica are reaching the end of the
follow-up period offered in the vaccine trial protocol, and as a result they are being
offered the chance to have complementary vaccinations against HPV, hepatitis A, and hepatitis
B.
Objectives:
- To offer participants in the Costa Rica Vaccine Trial the vaccine that they did not
receive during the masked portion of the trial (HPV vaccine or hepatitis A vaccine) and
hepatitis B vaccination.
- To collect information about exposure to known and suspected risk factors for HPV
infection and cervical cancer from women who are receiving vaccination against HPV at
crossover.
Eligibility:
- Women who participated in National Cancer Institute Protocol 04-C-N191.
Design:
- All participants will be offered vaccination against hepatitis B.
- Women who received the hepatitis A vaccine during the trial will be offered vaccination
against HPV.
- Women who received the HPV vaccine during the trial will be offered vaccination against
hepatitis A.
- Appropriate vaccinations (including a combined hepatitis A and hepatitis B vaccine) will
be available to reduce the number of injections that participants will be asked to
receive.
- All vaccines will be given according to the manufacturer's specifications for
appropriate length of time between vaccine doses.
Status | Completed |
Enrollment | 5444 |
Est. completion date | March 17, 2015 |
Est. primary completion date | |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 21 Years to 30 Years |
Eligibility |
- INCLUSION CRITERIA: To be eligible to receive crossover vaccination, participants must fulfill all of the following inclusion criteria: - Participation Status: Women previously randomized into the HPV-16/18 vaccine trial 04-C-N191, also known as the Costa Rica Vaccine Trial. - Planned Residence: Residents of Guanacaste or Puntarenas Province or willingness to visit one of the study clinics for participation. - Consent: Written informed consent obtained prior to enrollment into the crossover protocol. EXCLUSION CRITERIA: The following criteria will be checked for all potential participants at the time of enrollment. If any apply, the participant will not be included in the study. - History of (a) allergic reaction (e.g., difficulty breathing) after receipt of any vaccine, (b) hypersensitivity to latex. - History of vaccine related adverse events during the vaccination phase that, at the discretion of the investigators, preclude vaccination during the crossover phase. - Are receiving vaccination with Cervarix , are sexually experienced and of childbearing potential (i.e., not surgically sterilized), and are unwilling to use an effective method of birth control for 30 days before vaccination until 60 days after the last Cervarix vaccination (approximately 9 months). Acceptable forms of birth control include abstinence, surgical sterilization, hormonal contraceptives (e.g., oral, injectable, implant, and patch), intrauterine devices, and diaphragm or condom. - History of chronic condition that per attending doctor opinion precludes her from receiving vaccination (e.g., no proper treatment available or participant is unwilling to stay under proper treatment). - The participant has a diagnosed autoimmune illness (per the specific requirement of the INCIENSA IRB). - The vaccine or vaccines the participant is interested in receiving are contraindicated in her case. |
Country | Name | City | State |
---|---|---|---|
Costa Rica | Proyecto Epidemiologico Guanaste (PEG) | San Jose |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
Costa Rica,
Herrero R, Brinton LA, Reeves WC, Brenes MM, Tenorio F, de Britton RC, Gaitan E, Garcia M, Rawls WE. Invasive cervical cancer and smoking in Latin America. J Natl Cancer Inst. 1989 Feb 1;81(3):205-11. — View Citation
Herrero R, Schiffman MH, Bratti C, Hildesheim A, Balmaceda I, Sherman ME, Greenberg M, Cárdenas F, Gómez V, Helgesen K, Morales J, Hutchinson M, Mango L, Alfaro M, Potischman NW, Wacholder S, Swanson C, Brinton LA. Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project. Rev Panam Salud Publica. 1997 May;1(5):362-75. — View Citation
Reeves WC, Brinton LA, García M, Brenes MM, Herrero R, Gaitán E, Tenorio F, de Britton RC, Rawls WE. Human papillomavirus infection and cervical cancer in Latin America. N Engl J Med. 1989 Jun 1;320(22):1437-41. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00956553 -
Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls
|
Phase 4 | |
Completed |
NCT05372016 -
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
|
Phase 3 | |
Recruiting |
NCT05027776 -
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
|
Phase 3 | |
Suspended |
NCT00733122 -
Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)
|
Phase 3 | |
Recruiting |
NCT04895020 -
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
|
Phase 3 | |
Recruiting |
NCT05371353 -
Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
|
||
Completed |
NCT03900572 -
A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine
|
Phase 1 | |
Completed |
NCT00635830 -
An Open-Label, Single Dose Safety Study of Quadrivalent HPV Vaccine in Chinese Female Subjects (V501-035)
|
Phase 1 | |
Not yet recruiting |
NCT01021904 -
Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China
|
Phase 4 | |
Completed |
NCT00378560 -
V501 Efficacy Study in Women Aged 18 to 26 (V501-027)
|
Phase 2 | |
Completed |
NCT00682812 -
Significance of the High-risk Hpv Viral Load
|
N/A | |
Completed |
NCT00711815 -
A Study to Identify Markers in Blood and Tissue of HPV Clearance
|
N/A | |
Completed |
NCT00834106 -
Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)
|
Phase 3 | |
Completed |
NCT03085381 -
A Phase I Study of Quadrivalent HPV Recombinant Vaccine
|
Phase 1 | |
Completed |
NCT00847340 -
Human Papillomavirus (HPV) Genotypes in Genital Warts in Colombian Population
|
N/A | |
Completed |
NCT00411749 -
V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)
|
Phase 2 | |
Completed |
NCT00943722 -
A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)
|
Phase 3 |